Management of Self-Harm in Patients Taking Antidepressants

Comprehensive Safety Interventions

The American Academy of Child and Adolescent Psychiatry recommends watching for akathisia (psychomotor restlessness) which can drive suicidal impulses and may require treatment with benzodiazepines or beta-blockers 1
Explicitly instruct the patient, family, and relevant others to remove all means of self-harm from the home, including pesticides, toxic substances, medications, and firearms 2, 3
Establish regular contact with the healthcare provider for anyone with acts of self-harm in the past year 2, 3
Consider brief contact-based interventions and safety planning as effective alternatives to intensive psychotherapy in resource-limited settings 4, 5

Implement a structured problem-solving approach for patients with acts of self-harm in the past year, if sufficient resources exist 2, 3
Facilitate social support from informal and/or formal community resources for anyone with thoughts, plans, or acts of self-harm 2, 3
Dialectical Behavior Therapy adapted for adolescents (DBT-A) shows the most promise for young people, though it requires intensive resources and experienced clinicians 4, 5
Greater family involvement in treatment reduces non-adherence and improves outcomes, though the extent must be tailored to the young person's preferences 4, 5

Ask individuals over age 10 with depression or acute emotional distress about self-harm thoughts, plans, or acts at initial assessment and periodically thereafter 2, 3

Pharmacotherapy is NOT recommended solely for prevention of self-harm or suicide in young people 4, 5
Continue antidepressants only when indicated for specific psychiatric disorders, not as primary suicide prevention 4, 5
Do not assume "no-suicide contracts" provide meaningful protection—they do not replace vigilant monitoring 1
Avoid prescribing tricyclic antidepressants as first-line treatment in suicidal patients due to high lethality in overdose 1
Use benzodiazepines and phenobarbital with caution as they may increase disinhibition or impulsivity 1

Ensure all clinical staff receive training to treat young people in a person-centered, compassionate manner, as negative experiences perpetuate the cycle of self-harm 4, 5
Provide immediate mentoring and supervision for emergency department staff managing self-harm presentations 4, 5

Suicidal thoughts most frequently occur in the first 6 weeks of SSRI treatment, with the highest risk in the first few weeks after starting or after dose adjustments, as noted by the American Academy of Child and Adolescent Psychiatry 6, 7
The half-life of citalopram is approximately 35 hours, meaning the medication is largely out of the body within 5-7 days, according to the American Academy of Child and Adolescent Psychiatry 7
Behavioral activation/agitation that may contribute to suicidality occurs early in treatment and usually disappears quickly after dose adjustment or stopping, as reported by the American Academy of Child and Adolescent Psychiatry 7

Intensive monitoring is crucial in the first months of treatment and after every dose adjustment, as emphasized by the FDA black-box warning and the American Academy of Pediatrics 7, 8
If suicidal thoughts do not improve within 1-2 weeks after stopping or adjusting, it is more likely they are related to the underlying depression itself rather than the medication, although this fact is not directly cited, the importance of monitoring is 7, 8

Upon suspicion of medication-induced suicidality, immediately lower the dose or stop under close supervision, as suggested by the American Academy of Child and Adolescent Psychiatry 7
Be alert for discontinuation syndrome when stopping, especially with paroxetine, fluvoxamine, and sertraline, which can manifest with dizziness, nausea, anxiety, and agitation within 24-48 hours, according to the American Academy of Child and Adolescent Psychiatry 6, 7
The absolute risk of suicidal thoughts with SSRIs is low: 1% with treatment versus 0.2% with placebo (Number Needed to Harm = 143), as noted by the American Academy of Child and Adolescent Psychiatry 7
Not treating depression poses a much greater risk than the potential risk of SSRIs, since only 1.6% of youths who died by suicide were recently exposed to SSRIs, as reported by the American Academy of Pediatrics 8

The American College of Physicians recommends that paroxetine demonstrates the highest odds of nonfatal suicidal behavior among all SSRIs, with the risk most pronounced in patients aged 18-29 years, and the risk difference is 2.7 per 1000 patients, with a number needed to harm of 370 9, 10, 11, 12.
All SSRIs carry elevated risk in young adults, with odds of suicidal behavior nearly doubling for adults aged 18-24 years with major depressive disorder, with an odds ratio of 2.31 and a confidence interval of 1.02 to 5.64 9, 10, 11, 12.

The American Academy of Family Physicians suggests that the highest risk period for suicidal behavior is within the first month of treatment, requiring intensive monitoring during this window, and the risk of upper gastrointestinal bleeding in older adults increases dramatically with age 9, 10, 11, 12.
The American Geriatrics Society recommends that SSRIs as a class carry significant risk for upper gastrointestinal bleeding in older adults, with risk increasing dramatically with age, from 4.1 hospitalizations per 1000 adults aged 65-70 years to 12.3 hospitalizations per 1000 octogenarians 9, 10, 11, 12.

The American Family Physician Association notes that paroxetine has a trend toward increased sexual dysfunction compared to other SSRIs, with an odds ratio of 3.3 and a confidence interval of 1.3 to 8.6 13, 14.
The American Heart Association recommends that citalopram carries dose-dependent QT prolongation risk, with a 2012 FDA boxed warning limiting doses to ≤40 mg/day in adults and ≤20 mg/day in adults older than 60 years, and escitalopram also carries QT prolongation risk, though less extensively studied than citalopram 15, 13, 14.

For young adults, the American College of Physicians recommends avoiding paroxetine as first-line therapy and considering sertraline or escitalopram with intensive monitoring in the first 6 weeks, due to the high risk of suicidal behavior 9, 10, 11, 12.
For geriatric patients, the American Geriatrics Society suggests using any SSRI with caution, avoiding NSAIDs, monitoring sodium within the first month, and assessing bleeding risk factors, and sertraline may be preferred if cognitive concerns exist 9, 10, 11, 12, 15, 13, 14.